Regeneron and Sanofi's Dupixent receives Priority Review from FDA for adolescent chronic rhinosinusitis.

Regeneron and Sanofi's Dupixent (dupilumab) received Priority Review from the FDA for an sBLA as an add-on treatment for 12-17 y/o adolescents with inadequately controlled chronic rhinosinusitis w/ nasal polyposis (CRSwNP), potentially becoming the first treatment in this age group. If approved, Dupixent would offer significant improvements in treatment, diagnosis, or prevention of serious conditions.